# Minimal / molecular residual disease (MRD)

Source: https://onco.cc/terms/mrd/  
OnCo record `mrd` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer still present after treatment but too small to see on scans, detected by blood or marrow tests.

## Summary

Minimal or molecular residual disease (MRD), also called measurable residual disease, is cancer that persists after treatment at a level too small to see on scans but detectable in blood or marrow; a negative result is called molecular remission. In leukaemia and myeloma it is measured by flow cytometry or NGS of marrow (clonoSEQ); in solid tumours it means ctDNA after surgery, covered under MRD / molecular residual disease testing. MRD positivity predicts relapse, MRD-guided escalation (IMvigor011) and de-escalation (DYNAMIC) are proven concepts, and MRD is an accepted endpoint in myeloma trials (FDA ODAC 2024). Readers meet it in the Colorectal, Pancreatic, Bladder & urothelial, DLBCL and Multiple myeloma entries and in CIRCULATE-Japan.

## Fields

- Kind: Term
- Last checked: 2026-09-04
- Also known as: MRD-directed; MRD-negativity; measurable residual disease; minimal residual disease; molecular remission

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Minimal_residual_disease
- Wikipedia: https://en.wikipedia.org/wiki/Minimal_residual_disease

## Connected records

- technologies: [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Continuous and near-continuous ctDNA monitoring](https://onco.cc/technologies/continuous-ctdna-monitoring/), [ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)](https://onco.cc/technologies/ctdna-lymphoma-monitoring/), [Immunoglobulin and T-cell receptor clonality testing](https://onco.cc/technologies/clonality-testing/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Multiparameter flow cytometry MRD](https://onco.cc/technologies/flow-cytometry-mrd/), [NGS-based MRD (clonoSEQ and molecular MRD)](https://onco.cc/technologies/ngs-mrd-clonoseq/)
- trials: [ALTAIR](https://onco.cc/trials/altair/), [Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)](https://onco.cc/trials/autogene-cevumeran-phase-1/), [BESPOKE CRC](https://onco.cc/trials/bespoke-crc/), [CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)](https://onco.cc/trials/circulate-japan/), [CIRCULATE-US](https://onco.cc/trials/circulate-us/), [DYNAMIC](https://onco.cc/trials/dynamic/), [DYNAMIC-III](https://onco.cc/trials/dynamic-iii/), [IMvigor011](https://onco.cc/trials/imvigor011/), [MERMAID-1](https://onco.cc/trials/mermaid-1/), [MERMAID-2](https://onco.cc/trials/mermaid-2/), [TRACC](https://onco.cc/trials/tracc/)
- cancers: [Acute myeloid leukaemia in children](https://onco.cc/cancers/aml-paediatric/), [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Chronic myeloid leukaemia, chronic phase](https://onco.cc/cancers/cml-chronic-phase/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hairy cell leukaemia](https://onco.cc/cancers/hairy-cell-leukemia/), [High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)](https://onco.cc/cancers/all-paediatric-high-risk/), [Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)](https://onco.cc/cancers/all-infant/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia](https://onco.cc/cancers/aml-npm1-kmt2a/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)](https://onco.cc/cancers/all-ph-like/), [Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)](https://onco.cc/cancers/all-paediatric-ph-positive/), [Relapsed and refractory acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-relapsed/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/), [Standard-risk B-cell acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-standard-risk/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- ideas: [A bone marrow niche on a chip to study human dormancy](https://onco.cc/ideas/idea-bio2-marrow-niche-on-chip/), [A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection](https://onco.cc/ideas/idea-gbc-ctdna-residual-disease-guided-adjuvant-trial/), [A dedicated clinic for people whose blood test says the cancer is back](https://onco.cc/ideas/idea-bio2-mrd-clinic-service/), [A national platform trial that every ctDNA-positive patient can join](https://onco.cc/ideas/idea-bio2-national-mrd-platform/), [A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled](https://onco.cc/ideas/idea-moon-mrd-weather-service/), [A ring-fenced metastasis programme with metastasis-specific endpoints](https://onco.cc/ideas/idea-fund-metastasis-moonshot/), [An independent programme that validates surrogate endpoints, setting by setting](https://onco.cc/ideas/idea-tr1-surrogate-validation-programme/), [Bank yearly blood from cancer survivors so future tests can be validated](https://onco.cc/ideas/idea-bio2-survivor-plasma-biobank/), [Block the recycling that keeps dormant cells alive](https://onco.cc/ideas/idea-bio2-autophagy-block-mrd/), [Blunt the inflammation that wakes sleeping cancer cells](https://onco.cc/ideas/idea-bio2-il1-awakening-blockade/), [Certified reference samples to benchmark every tumour-DNA blood test](https://onco.cc/ideas/idea-tr2-ctdna-reference-plasma/), [Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs](https://onco.cc/ideas/idea-bio2-ctc-clearance-go-nogo/), [ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative](https://onco.cc/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/), [ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer](https://onco.cc/ideas/idea-ctdna-guided-adjuvant-crc/), [ctDNA-guided adjuvant therapy in stage II-III melanoma](https://onco.cc/ideas/idea-ctdna-guided-adjuvant-melanoma/), [ctDNA-guided duration of PARP maintenance](https://onco.cc/ideas/idea-ctdna-guided-parp-duration/), [ctDNA-guided escalation and de-escalation in frontline DLBCL](https://onco.cc/ideas/idea-ctdna-guided-dlbcl-frontline/), [ctDNA-triggered escalation in early TNBC](https://onco.cc/ideas/idea-ctdna-escalation-tnbc/), [Cut off the emergency programme cancer cells use to survive treatment](https://onco.cc/ideas/idea-bio1-stress-response-blockade/), [Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells](https://onco.cc/ideas/idea-moon-dormancy-eradication-programme/), [Find peritoneal spread while it is still small, and run complete cytoreduction through networks rather than adding heated chemotherapy](https://onco.cc/ideas/idea-crc-peritoneal-disease-found-early-and-treated-in-networks/), [Flush dormant cells out of bone marrow, then kill them](https://onco.cc/ideas/idea-bio2-cxcr4-mobilise-then-kill/), [Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials](https://onco.cc/ideas/idea-tr2-ctdna-mrd-qualification/), [HPV circulating tumour DNA to guide cervical cancer therapy](https://onco.cc/ideas/idea-hpv-ctdna-cervical/), [Intercepting late recurrence with ctDNA surveillance and oral SERDs](https://onco.cc/ideas/idea-late-recurrence-interception/), [Keep dormant cells asleep instead of trying to kill them](https://onco.cc/ideas/idea-bio2-pro-dormancy-therapy/), [Keep them asleep: dormancy maintenance as adjuvant therapy](https://onco.cc/ideas/idea-dormancy-maintenance-therapy/), [Kill the sleeping survivor cells with iron-dependent cell death](https://onco.cc/ideas/idea-bio1-persister-ferroptosis/), [Metastasis prevention as a formal indication with its own trials and regulatory pathway](https://onco.cc/ideas/idea-moon-metastasis-prevention-indication/), [Off-the-shelf natural killer cells to sweep up residual disease](https://onco.cc/ideas/idea-bio2-nk-cells-for-mrd/), [Outcome-based annuity payments for potentially curative one-time therapies](https://onco.cc/ideas/idea-fund-pay-for-cure-annuities/), [Personalised vaccines given only when the blood test turns positive](https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/), [Plan the second CAR-T target before the first one is lost](https://onco.cc/ideas/idea-bio1-adaptive-car-antigen-switch/), [Push residual disease detection a hundredfold deeper with whole-genome methods](https://onco.cc/ideas/idea-bio2-whole-genome-mrd-depth/), [Read the spinal fluid to track brain tumours without opening the skull](https://onco.cc/ideas/idea-bio2-csf-ctdna-monitoring/), [Reference materials and open proficiency testing for residual disease tests](https://onco.cc/ideas/idea-bio2-mrd-reference-standards/), [Starve the survivors: target the energy pathway drug-tolerant cells switch to](https://onco.cc/ideas/idea-bio1-persister-metabolic-vulnerability/), [Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps](https://onco.cc/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/), [Take the blood test, and give the drug, at the right time of day](https://onco.cc/ideas/idea-bio2-circadian-mrd-sampling/), [Use circulating tumour DNA instead of the interim scan to decide what happens next](https://onco.cc/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/), [Use residual disease tests to decide who needs ten years of hormone therapy](https://onco.cc/ideas/idea-bio2-mrd-guided-endocrine-duration/)
- terms: [B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)](https://onco.cc/terms/b-all-cytogenetic-risk/), [Cell-free DNA (cfDNA)](https://onco.cc/terms/cfdna/), [Clonal evolution and the ecological view of cancer](https://onco.cc/terms/clonal-evolution-theory/), [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/), [Colorectal cancer: the failed and stopped programmes, and why](https://onco.cc/terms/colorectal-failed-programmes/), [Disseminated tumour cells (DTCs)](https://onco.cc/terms/disseminated-tumor-cells/), [Event-free / disease-free survival (EFS, DFS, iDFS, RFS)](https://onco.cc/terms/efs/), [Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [Immunoscore](https://onco.cc/terms/immunoscore/), [Leukaemia (tissue type)](https://onco.cc/terms/leukaemia-type/), [M-protein, immunofixation and serum free light chains](https://onco.cc/terms/m-protein-free-light-chains/), [MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)](https://onco.cc/terms/mrd-negativity-myeloma/), [MRD-negative complete remission](https://onco.cc/terms/mrd-negative-cr/), [Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia](https://onco.cc/terms/ph-like-all/), [Recurrence and relapse](https://onco.cc/terms/relapse-recurrence/), [Remission](https://onco.cc/terms/remission/), [SMART design (sequential multiple assignment randomised trial)](https://onco.cc/terms/smart-design/), [Surrogate endpoint](https://onco.cc/terms/surrogate-endpoint/), [Surrogate endpoint validation: which stand-ins have earned trust](https://onco.cc/terms/surrogate-validation/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/), [Umbrella trial](https://onco.cc/terms/umbrella-trial/), [Undetectable MRD (uMRD / MRD-negative)](https://onco.cc/terms/umrd/)
- key papers: [ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-adaura-nejm-2020/), [Alectinib in resected ALK-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/), [AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients](https://onco.cc/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/), [Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer](https://onco.cc/key-papers/paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019/), [Assessment of molecular relapse detection in early-stage breast cancer](https://onco.cc/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/), [Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial](https://onco.cc/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/), [c-TRAK TN analysis: tissue-free versus tumour-informed ctDNA assays for residual disease in early triple-negative breast cancer](https://onco.cc/key-papers/paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026/), [Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL](https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/), [Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer](https://onco.cc/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/), [Circulating tumor DNA as a clinical test in resected pancreatic cancer](https://onco.cc/key-papers/paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019/), [Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer](https://onco.cc/key-papers/paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019/), [Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences](https://onco.cc/key-papers/paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022/), [Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients](https://onco.cc/key-papers/paper-sausen-ctdna-pancreatic-resection-nat-commun-2015/), [CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients](https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/), [ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease](https://onco.cc/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/), [Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection](https://onco.cc/key-papers/paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025/), [Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumour DNA](https://onco.cc/key-papers/paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016/), [DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer](https://onco.cc/key-papers/paper-dynamic-nejm-2022/), [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/), [GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold](https://onco.cc/key-papers/paper-galaxy-signatera-nat-med-2023/), [IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery](https://onco.cc/key-papers/paper-imvigor011-nejm-2025/), [INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL](https://onco.cc/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/), [MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL](https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/), [Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer](https://onco.cc/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/), [Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution](https://onco.cc/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/), [Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker](https://onco.cc/key-papers/paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017/), [Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission](https://onco.cc/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/), [Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer](https://onco.cc/key-papers/paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026/), [Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer](https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/), [TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse](https://onco.cc/key-papers/paper-tracerx-evolution-nature-2023/), [TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse](https://onco.cc/key-papers/paper-tracerx-100-nejm-2017/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/), [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- biomarkers: [BCL2 G101V and the other venetoclax binding-site mutations](https://onco.cc/biomarkers/bcl2-g101v/), [BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)](https://onco.cc/biomarkers/bcr-abl1-transcript/), [CD19 expression (CD19-positive)](https://onco.cc/biomarkers/cd19-expression/), [ctDNA MRD positivity (molecular residual disease after curative treatment)](https://onco.cc/biomarkers/ctdna-mrd-positive/), [Immunoglobulin and T-cell receptor clonality](https://onco.cc/biomarkers/ig-tcr-clonality/), [NPM1 mutation](https://onco.cc/biomarkers/npm1-mutation/)
- companies: [Allogene Therapeutics](https://onco.cc/companies/allogene/), [Australasian Gastro-Intestinal Trials Group](https://onco.cc/companies/agitg/), [Foresight Diagnostics](https://onco.cc/companies/foresight-diagnostics/), [GIMEMA](https://onco.cc/companies/gimema/), [HOVON](https://onco.cc/companies/hovon/), [Personalis (Tempus)](https://onco.cc/companies/personalis/)
- pairings: [ctDNA MRD → adjuvant therapy decision](https://onco.cc/pairings/ctdna-mrd-to-adjuvant/)
- people: [Ash A. Alizadeh](https://onco.cc/people/ash-alizadeh/), [Klaus Pantel](https://onco.cc/people/klaus-pantel/), [Maximilian Diehn](https://onco.cc/people/maximilian-diehn/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/)
- pathways: [Clonal evolution & minimal residual disease](https://onco.cc/pathways/clonal-evolution/), [Drug-tolerant persister cells](https://onco.cc/pathways/drug-tolerant-persisters/), [Intravasation & circulating tumour cells](https://onco.cc/pathways/intravasation-ctc-survival/), [The metastatic cascade](https://onco.cc/pathways/metastatic-cascade/), [The pre-metastatic niche](https://onco.cc/pathways/pre-metastatic-niche/), [Tumour dormancy](https://onco.cc/pathways/tumor-dormancy/)
- institutions: [American Society of Hematology](https://onco.cc/institutions/ash/), [Cancer Center Clínica Universidad de Navarra / CIMA](https://onco.cc/institutions/cun-navarra/), [European Hematology Association](https://onco.cc/institutions/eha/), [Hospital Universitario 12 de Octubre](https://onco.cc/institutions/12-de-octubre/), [INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia](https://onco.cc/institutions/incliva-valencia/), [IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)](https://onco.cc/institutions/iuct-oncopole/), [National Cancer Center Hospital East](https://onco.cc/institutions/ncc-hospital-east/), [Sydney Children's Hospitals Network / Children's Cancer Institute](https://onco.cc/institutions/sydney-childrens-hospitals-network/), [Sylvester Comprehensive Cancer Center, University of Miami](https://onco.cc/institutions/sylvester-miami/)
- drugs: [clonoSEQ](https://onco.cc/drugs/clonoseq/), [Guardant Reveal](https://onco.cc/drugs/guardant-reveal/), [Oncodetect](https://onco.cc/drugs/oncodetect/), [RaDaR](https://onco.cc/drugs/radar-mrd/)

---
JSON: https://onco.cc/api/v1/entities/mrd.json